CDKL5 Deficiency Disorder Market to Witness Upsurge in Growth, Assesses DelveInsight | Key Companies in the Market - Jazz, Stoke, Epygenix, Zogenix, UCB Pharma, Takeda, Eisai, Longboard, Marinus - Seite 3

Several drugs (anticonvulsant monotherapy) are indicated to manage CDKL5 symptoms, and surgical procedures are used when medication is ineffective. In many situations, physical symptoms of CDKL5 can be eased and managed with a comprehensive treatment plan that includes occupational therapy, speech therapy, and visual therapy. Dietary changes, such as the ketogenic diet, have shown inconsistent improvement in some people with autistic tendencies. These strict dietary adjustments, however, must be implemented under close medical supervision and can be taxing on families. Physiotherapy/physical treatment can also help to improve overall muscle tone, trunk stability, strength, balance, foot deformity prevention, foot alignment, and heel cord lengthening.

To know more about CDKL5 deficiency disorder treatment, visit @ CDKL5 Deficiency Disorder Treatment Drugs 

Key CDKL5 Deficiency Disorder Therapies and Companies

• GWP42003-P: Jazz Pharmaceuticals
• STK-001: Stoke Therapeutics, Inc
• EPX-100: Epygenix
• ZX008: Zogenix, Inc./UCB Pharma
• Soticlestat: Takeda
• Lorcaserin: Eisai Inc.
• LP352: Longboard Pharmaceuticals
• Ganaxolone: Marinus Pharmaceuticals

Learn more about the FDA-approved drugs for CDKL5 deficiency disorder @ Drugs for CDKL5 Deficiency Disorder Treatment 

CDKL5 Deficiency Disorder Market Dynamics

The dynamics of the CDKL5 deficiency disorder market are expected to change in the coming years. The increase in awareness and technology, the increasing prevalent population of the disease, perks related to rare diseases, and others are fueling the CDKL5 deficiency disorder market growth.  Moreover, the expected introduction of emerging therapies with improved efficacy, more awareness initiatives programs, and a further improvement in the diagnosis rate are likely to boost the growth of the CDKL5 deficiency disorder market in the 7MM. 

However, several factors are impeding the growth of the CDKL5 deficiency disorder market. The poor prognosis of the disease and the limited understanding of the disease mechanism are the two prominent factors affecting the growth of the CDKL5 deficiency disorder market.  Furthermore, the CDKL5 deficiency disorder market growth may be offset by failures and discontinuation of emerging therapies, unaffordable pricing, market access and reimbursement issues, and a shortage of healthcare specialists. In addition, the undiagnosed, unreported cases and the unawareness about the disease may also impact the CDKL5 deficiency disorder market growth.